The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
A translational framework to DELIVER nanomedicines to the clinic
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“Liposomal doxorubicin, Doxil, was the first nanomedicine to overcome the translational hurdles and was approved for clinical use in 1995 6 .”
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · cited 1×
“A key example lies in the recent development of lipid nanoparticle-based mRNA vaccines where the nanoparticle composition, ionizable lipid chemistry, mRNA construct and manufacturing process all form inventive aspects 82 .”
Self-citationWhat does research reproducibility mean?
Goodman, S. N., Fanelli, D., & Ioannidis, J. P. A. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5027 · Cited by 1,293
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Self-citationFogel, D. B. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.001 · Cited by 1,035
Minimum information reporting in bio–nano experimental literature
Faria, M., Björnmalm, M., Thurecht, K. J., Kent, S. J., Parton, R. G., Kavallaris, M., Johnston, A. P. R., Gooding, J. J., Corrie, S. R., Boyd, B. J., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0246-4 · Cited by 710
Self-citationImproving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W., Cuthill, I., Emerson, M., & Altman, D. (2014) · Animals · doi:10.3390/ani4010035 · Cited by 707
The protein corona from nanomedicine to environmental science
Mahmoudi, M., Landry, M. P., Moore, A., & Coreas, R. (2023) · Nature Reviews Materials · doi:10.1038/s41578-023-00552-2 · Cited by 625
The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine
Cai, R., & Chen, C. (2019) · Advanced Materials · doi:10.1002/adma.201805740 · Cited by 589
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures
He, H., Liu, L., Morin, E. E., Liu, M., & Schwendeman, A. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00228 · Cited by 588
Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020) · Biomaterials Science · doi:10.1039/d0bm00558d · Cited by 568
Nanomedicines: addressing the scientific and regulatory gap
Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. (., Tamarkin, L., & Desai, N. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12403 · Cited by 546
Nanomedicine scale-up technologies: feasibilities and challenges
Paliwal, R., Babu, R. J., & Palakurthi, S. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0177-9 · Cited by 466
Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts
Hoffman, R. M. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3972 · Cited by 425
Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future
Arden, N. S., Fisher, A. C., Tyner, K., Yu, L. X., Lee, S. L., & Kopcha, M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120554 · Cited by 420
Bhatia, S. N., Chen, X., Dobrovolskaia, M. A., & Lammers, T. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00496-9 · Cited by 406
Self-citationDelivering the power of nanomedicine to patients today
Germain, M., Caputo, F., Metcalfe, S., Tosi, G., Spring, K., Åslund, A. K. O., Pottier, A., Schiffelers, R., Ceccaldi, A., & Schmid, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.007 · Cited by 405
Self-citationChallenges in nanomedicine clinical translation
Metselaar, J. M., & Lammers, T. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00740-5 · Cited by 396
Self-citationDrugs, Devices, and the FDA: Part 1
Van Norman, G. A. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.002 · Cited by 366
Hadjidemetriou, M., Al-Ahmady, Z., Mazza, M., Collins, R. F., Dawson, K., & Kostarelos, K. (2015) · ACS Nano · doi:10.1021/acsnano.5b03300 · Cited by 358
Zushin, P.-J. H., Mukherjee, S., & Wu, J. C. (2023) · Journal of Clinical Investigation · doi:10.1172/jci175824 · Cited by 347
Current approaches of nanomedicines in the market and various stage of clinical translation
Shan, X., Gong, X., Li, J., Wen, J., Li, Y., & Zhang, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.025 · Cited by 335
Ban, Z., Yuan, P., Yu, F., Peng, T., Zhou, Q., & Hu, X. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919755117 · Cited by 313
Perspectives on the past, present, and future of cancer nanomedicine
Youn, Y. S., & Bae, Y. H. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.05.008 · Cited by 285
Li, J., & Kataoka, K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09029 · Cited by 281
Crist, R. M., Grossman, J. H., Patri, A. K., Stern, S. T., Dobrovolskaia, M. A., Adiseshaiah, P. P., Clogston, J. D., & McNeil, S. E. (2013) · Integrative Biology · doi:10.1039/c2ib20117h · Cited by 265
Challenges in design of translational nanocarriers
Sun, Q., Radosz, M., & Shen, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.042 · Cited by 261
Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects
Zhang, P., Xiao, Y., Sun, X., Lin, X., Koo, S., Yaremenko, A. V., Qin, D., Kong, N., Farokhzad, O. C., & Tao, W. (2023) · Med · doi:10.1016/j.medj.2022.12.001 · Cited by 249
Waterhouse, D. N., Tardi, P. G., Mayer, L. D., & Bally, M. B. (2001) · Drug Safety · doi:10.2165/00002018-200124120-00004 · Cited by 242
On the issue of transparency and reproducibility in nanomedicine
Leong, H. S., Butler, K. S., Brinker, C. J., Azzawi, M., Conlan, S., Dufés, C., Owen, A., Rannard, S., Scott, C., Chen, C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0496-9 · Cited by 242
Self-citationCancer nanomedicine: is targeting our target?
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 233
Self-citationShitara, K., Takashima, A., Fujitani, K., Koeda, K., Hara, H., Nakayama, N., Hironaka, S., Nishikawa, K., Makari, Y., Amagai, K., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30219-9 · Cited by 217
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
Yuan, D., He, H., Wu, Y., Fan, J., & Cao, Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.10.037 · Cited by 186
Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1990 · Cited by 183
Harrington, K. J., Lewanski, C. R., Northcote, A. D., Whittaker, J., Wellbank, H., Vile, R. G., Peters, A. M., & Stewart, J. S. W. (2001) · Annals of Oncology · doi:10.1023/a:1011199028318 · Cited by 182
Tang, H., Zhang, Y., Yang, T., Wang, C., Zhu, Y., Qiu, L., Liu, J., Song, Y., Zhou, L., Zhang, J., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01455-7 · Cited by 177
Ioannidis, J. P. A., Kim, B. Y. S., & Trounson, A. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0314-y · Cited by 175
The beginning of the end of the nanomedicine hype
Park, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.044 · Cited by 158
Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0391-z · Cited by 147
Milane, L. S., & Amiji, M. M. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00911-y · Cited by 122
Progress and challenges in the translation of cancer nanomedicines
Tong, F., Wang, Y., & Gao, H. (2023) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2023.103045 · Cited by 119
In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link?
Jain, P., Pawar, R. S., Pandey, R. S., Madan, J., Pawar, S., Lakshmi, P. K., & Sudheesh, M. S. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.08.003 · Cited by 117
Nanomedicine: controlling nanoparticle clearance for translational success
Zhu, G. H., Gray, A. B. C., & Patra, H. K. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.05.001 · Cited by 117
Thomas, V. J., Bliemel, M., Shippam, C., & Maine, E. (2020) · Technovation · doi:10.1016/j.technovation.2020.102153 · Cited by 111
López-Estévez, A. M., Lapuhs, P., Pineiro‐Alonso, L., & Alonso, M. J. (2023) · Advanced Materials · doi:10.1002/adma.202309355 · Cited by 107
Self-citationSelf-driving laboratories: A paradigm shift in nanomedicine development
Hickman, R. J., Bannigan, P., Bao, Z., Aspuru‐Guzik, A., & Allen, C. J. (2023) · Matter · doi:10.1016/j.matt.2023.02.007 · Cited by 104
Self-citationChetwynd, A. J., Wheeler, K. E., & Lynch, I. (2019) · Nano Today · doi:10.1016/j.nantod.2019.06.004 · Cited by 101
de Vlieger, J. S. B., Crommelin, D. J. A., Tyner, K., Drummond, D. C., Jiang, W., McNeil, S. E., Neervannan, S., Crist, R. M., & Shah, V. P. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0329-7 · Cited by 100
Urbán, P., Liptrott, N. J., & Bremer, S. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1546 · Cited by 95
A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products
Troiano, G., Nolan, J., Parsons, D. M., Hoven, C. V. G., & Zale, S. E. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9969-z · Cited by 84
mRNA Cancer Vaccines: Construction and Boosting Strategies
Liu, X., Huang, P., Yang, R., & Deng, H. (2023) · ACS Nano · doi:10.1021/acsnano.3c05635 · Cited by 82
Jung, M., Ghamrawi, S., Du, E. Y., Gooding, J. J., & Kavallaris, M. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202200690 · Cited by 81
Self-citationDelivering nanomedicines to patients: A practical guide
Eaton, M., Lévy, L., & Fontaine, O. M. A. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.02.004 · Cited by 77
Histopathological biomarkers for predicting the tumour accumulation of nanomedicines
May, J., Moss, J. I., Mueller, F., Golombek, S. K., Biancacci, I., Rizzo, L. Y., Elshafei, A. S., Gremse, F., Pola, R., Pechar, M., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01197-4 · Cited by 74
Self-citationLong-term monitoring for nanomedicine implants and drugs
Kendall, M., & Lynch, I. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.341 · Cited by 67
PharmDE: A new expert system for drug-excipient compatibility evaluation
Wang, N., Huimin, S., Dong, J. N., & Ouyang, D. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120962 · Cited by 61
Atrafi, F., van Eerden, R. A. G., Vlieg, M. A. M. V. H., Hoop, E. O., de Bruijn, P., Lolkema, M. P., Moelker, A. D., Rijcken, C. J. F., Hanssen, R., Sparreboom, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0008 · Cited by 60
Self-citationNanomedicine at the crossroads – A quick guide for IVIVC
Mast, M.-P., Modh, H., Champanhac, C., Wang, J., Storm, G., Krämer, J., Mailänder, V., Pastorin, G., & Wacker, M. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113829 · Cited by 59
Active ingredient vs excipient debate for nanomedicines
Hemmrich, E., & McNeil, S. E. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01371-w · Cited by 54
Tackling the challenges of nanomedicines: are we ready?
Hertig, J. B., Shah, V. P., Flühmann, B., Mühlebach, S., Stemer, G., Surugue, J., Moss, R. L., & Francesco, T. D. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxab048 · Cited by 51
Protein adsorption determines pulmonary cell uptake of lipid-based nanoparticles
Subramaniam, S., Joyce, P. M., Donnellan, L., Young, C., Wignall, A. D., Hoffmann, P., & Prestidge, C. A. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.03.048 · Cited by 51
Self-citationEfficient non-viral CAR-T cell generation via silicon-nanotube-mediated transfection
Chen, Y., Mach, M., Shokouhi, A., Yoh, H. Z., Bishop, D. C., Murayama, T., Suu, K., Morikawa, Y., Barry, S. C., Micklethwaite, K. P., et al. (2023) · Materials Today · doi:10.1016/j.mattod.2023.02.009 · Cited by 44
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
Shin, S., Lee, P., Han, J., Kim, S.-N., Lim, J., Park, D.-H., Paik, T., Min, J., Park, C. G., & Park, W. (2023) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-022-00515-8 · Cited by 43
The potential of mRNA vaccines in cancer nanomedicine and immunotherapy
Pan, S., Fan, R., Han, B. R., Tong, A., & Guo, G. F. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.11.003 · Cited by 43
In vitro-in vivo correlation in nanocarriers: From protein corona to therapeutic implications
Agnihotri, T. G., Alexander, A., Agrawal, M., Dubey, S. K., & Jain, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.063 · Cited by 42
Optimal Use of the Non-Inferiority Trial Design
Angeli, F., Verdecchia, P., Vaudo, G., Masnaghetti, S., & Reboldi, G. (2020) · Pharmaceutical Medicine · doi:10.1007/s40290-020-00334-z · Cited by 39
Rapid response through the entrepreneurial capabilities of academic scientists
Park, A., Goudarzi, A., Yaghmaie, P., Thomas, V. J., & Maine, E. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01103-6 · Cited by 37
Evaluating Nanomedicines: Obstacles and Advancements
Swierczewska, M., Crist, R. M., & McNeil, S. E. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7352-1_1 · Cited by 36
Ke, W., Crist, R. M., Clogston, J. D., Stern, S. T., Dobrovolskaia, M. A., Grodzinski, P. A., & Jensen, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114591 · Cited by 36
The start-ups taking nanoneedles into the clinic
Elnathan, R., Tay, A. K. P., Voelcker, N. H., & Chiappini, C. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01158-5 · Cited by 35
Mi, J., Ye, Q., & Min, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849759 · Cited by 32
Young, H., He, Y., Joo, B. S., Ferguson, S., Demko, A., Butterfield, S. K., Lowe, J., Mjema, N. F., Sheth, V. M., Whitehead, L., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c04171 · Cited by 32
Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor
Zuo, Y.-H., Zhao, X., & Fan, X. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106454 · Cited by 28
Kosaka, Y., Saeki, T., Takano, T., Aruga, T., Yamashita, T., Masuda, N., Koibuchi, Y., Osaki, A., Watanabe, J., & Suzuki, R. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s372477 · Cited by 24
Bhattacharjee, S., & Brayden, D. J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1826434 · Cited by 22
Automating CAR‐T Transfection with Micro and Nano‐Technologies
Hu, T., Kumar, A. R. K., Luo, Y., & Tay, A. K. P. (2023) · Small Methods · doi:10.1002/smtd.202301300 · Cited by 22
Atrafi, F., Dumez, H., Mathijssen, R. H. J., van Oordt, C. W. M. D. H., Costermans, J., Rijcken, C. J. F., Hanssen, R., Eskens, F. A. L. M., & Schöffski, P. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3026 · Cited by 18
Self-citationBoere, I. A., Vergote, I. B., Hanssen, R., Jalving, M., Gennigens, C., Ottevanger, P. B., van de Wouw, Y., Rijcken, C. J. F., Mathijssen, R. H. J., & Ledermann, J. A. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004308 · Cited by 18
Self-citationA personal account of translating discoveries in an academic lab
Langer, R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2609 · Cited by 14
Self-citation
Cited by
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Jiao, Y., Yang, L., Wang, R., Song, G., Fu, J., Wang, J., Gao, N., & Wang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121611 · Cited by 63
Metadata
- Authors
- Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., Popat, A., Prestidge, C. A., Rijcken, C. J. F., Sarmento, B., Schmid, R. B., Schroeder, A., Subramaniam, S., Thorn, C. R., Whitehead, K. A., Zhao, C.-X., & Santos, H. A.
- Venue
- Nature Nanotechnology
- Published
- 2024-09-06
- Volume
- 19
- Issue
- 11
- Pages
- 1597-1611
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W4402316253
- Cited by
- 333
- References
- 81
- FWCI
- 27.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.